Calidi Biotherapeutics
CLDI
27 hedge funds and large institutions have $1.53M invested in Calidi Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
29% more funds holding
Funds holding: 21 → 27 (+6)
0% more ownership
Funds ownership: 0% → 0% (+0%)
46% less capital invested
Capital invested by funds: $2.83M → $1.53M (-$1.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RWI
Red Wave Investments
Dillsburg,
Pennsylvania
|
+$502K |
| 2 |
AMH
Apollo Management Holdings
New York
|
+$106K |
| 3 |
CI
CPR Investments
Rochester,
Michigan
|
+$58.8K |
| 4 |
EWM
Evermay Wealth Management
Arlington,
Virginia
|
+$53.9K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$52.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$154K |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
-$57.2K |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$32.7K |
| 4 |
Renaissance Technologies
New York
|
-$26K |
| 5 |
AWM
Axxcess Wealth Management
Carlsbad,
California
|
-$19.9K |
CLDI Hedge Fund Activity: Q1 2024 in Review
27 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2024, worth a combined $1.53M — down 46% from $2.83M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLDI positions and 4 closed out — a net gain of 6 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Red Wave Investments, adding an estimated $502K. The largest seller was Millennium Management, exiting entirely with an estimated $154K sold.
- 27 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2024, up from 21 in Q4 2023.
- Funds reported $1.53M of Calidi Biotherapeutics stock for Q1 2024, down 46% quarter-over-quarter.
- 10 funds opened new Calidi Biotherapeutics positions in Q1 2024 and 4 closed out, a net change of +6 holders.
- The largest Calidi Biotherapeutics buyer in Q1 2024 was Red Wave Investments, an estimated $502K added.
- The largest Calidi Biotherapeutics seller in Q1 2024 was Millennium Management, an estimated $154K sold.
Based on aggregated 13F filings for Q1 2024.